Allworth Financial LP Cuts Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Allworth Financial reduced its Thermo Fisher Scientific stake by 30.4% in the second quarter, selling 10,625 shares and retaining 24,334 shares valued at approximately $12.2 million.
• Thermo Fisher reported stronger-than-expected quarterly results, with EPS of $6.03 and revenue of $11.99 billion; revenue increased 10.5% year over year. The company reaffirmed fiscal 2026 EPS guidance of $24.93–$25.33.
• Analysts remain broadly positive, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $624.64. Thermo Fisher also declared a quarterly dividend of $0.47 per share, representing a 0.3% yield.

Allworth Financial LP lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 30.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 24,334 shares of the medical research company's stock after selling 10,625 shares during the quarter. Allworth Financial LP's holdings in Thermo Fisher Scientific were worth $12,200,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. California State Teachers Retirement System lifted its position in Thermo Fisher Scientific by 49,331.5% in the second quarter. California State Teachers Retirement System now owns 282,654,735 shares of the medical research company's stock valued at $141,711,778,000 after purchasing an additional 282,082,924 shares during the last quarter. J. Stern & Co. LLP increased its stake in shares of Thermo Fisher Scientific by 58,006.4% in the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company's stock worth $18,258,082,000 after buying an additional 31,455,105 shares during the period. BlackRock Inc. bought a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $15,501,867,000. State Street Corp boosted its position in Thermo Fisher Scientific by 1.4% during the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company's stock valued at $9,633,991,000 after buying an additional 229,630 shares during the period. Finally, Corient Private Wealth LP bought a new stake in Thermo Fisher Scientific in the 2nd quarter worth $382,547,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Down 1.7%

NYSE TMO opened at $603.43 on Wednesday. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $647.00. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The stock's fifty day moving average price is $575.12 and its 200-day moving average price is $516.59. The stock has a market cap of $223.12 billion, a P/E ratio of 32.46, a P/E/G ratio of 2.57 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the prior year, the firm posted $4.28 earnings per share. The business's revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio is 10.11%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CAO Joseph Holmes sold 420 shares of the company's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the sale, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Michael Shafer sold 25,500 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares of the company's stock, valued at $12,596,400. This represents a 54.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 73,768 shares of company stock worth $44,122,820 in the last quarter. Company insiders own 0.33% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on TMO. Stifel Nicolaus set a $650.00 price target on Thermo Fisher Scientific in a research report on Wednesday, August 5th. Royal Bank Of Canada boosted their target price on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a "sector perform" rating in a research note on Friday, July 24th. Evercore set a $570.00 price target on shares of Thermo Fisher Scientific in a report on Monday, July 6th. CLSA began coverage on shares of Thermo Fisher Scientific in a report on Thursday, September 3rd. They issued an "outperform" rating and a C$748.00 price objective for the company. Finally, Morgan Stanley raised their target price on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an "overweight" rating in a research report on Friday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $624.64.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.